Wang Yongzhong

Dr. Wang will bring over 20 years of innovation and leadership experience in global pharmaceutical and biotech industries.

He most recently held a role of President of Pharmaceuticals and EVP at Simcere, where he oversaw all pilot and commercial manufacturing operations including a Mab facility and a recombinant protein facility. He was also responsible for all quality operations including R&D, production and distribution, supply chain, engineering, regulatory affairs, and international sales. Among other duties, he also served as the Chairman of the Board for a joint venture for therapeutic DNA vaccines and on the joint steering committee for Simcere's strategic partnership in biosimilar with AMGEN.

Prior to Simcere, he served as the CEO at Kanghong Biotech, which successfully developed and launched Conbercept, the first innovative biological product with an international non-propriety name from China in 2014. Under his leadership, Conbercept became the market leader over international brands in China market in 2016. Dr. Wang further brought Conbercept to the global stage by clearing a FDA IND to directly enter phase III clinical trial in the USA, the first such case for innovative biological product from China. This achievement was voted as one of China's Top Ten Advancements in Pharmaceutical and Biotech Industries in 2016.

Earlier in his career, Dr. Wang worked at Genzyme in Cambridge, USA. He led CMC and quality projects for Carticel and Epicel, the first two approved cell therapy products by the FDA. He was also instrumental for the development and approval of MACI, the first issue-engineering product approved by FDA. He held two patents for MACI, both of which were used for commercial manufacturing.

Dr. Wang earned his PhD from the Chemicaland Biological Engineering Department at Tufts University in Boston and hisscientific publications have obtained over 3000 citations by peers in the biotech field.